

CITATION REPORT

List of articles citing

Intestinal microbiota in patients with chronic hepatitis C with and without cirrhosis compared with healthy controls

DOI: 10.1111/liv.13485

Liver International, 2018, 38, 50-58.

Source: <https://exaly.com/paper-pdf/69507326/citation-report.pdf>

Version: 2024-04-23

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
63	Diet affects gut microbiota and modulates hospitalization risk differentially in an international cirrhosis cohort. <i>Hepatology</i> , 2018 , 68, 234-247	11.2	59
62	Gut Dysbiosis Associated With Hepatitis C Virus Infection. <i>Clinical Infectious Diseases</i> , 2018 , 67, 869-877	11.6	85
61	The Gut-Liver Axis in Hepatitis C Virus Infection: A Path Towards Altering the Natural History of Fibrosis Progression?. <i>Clinical Infectious Diseases</i> , 2018 , 67, 878-880	11.6	1
60	Editorial: direct anti-viral agents, hepatitis C virus eradication, and gut-liver axis-another mechanistic piece to the puzzle. <i>Alimentary Pharmacology and Therapeutics</i> , 2018 , 48, 1321-1322	6.1	
59	The impact of proton pump inhibitors on the intestinal microbiota in chronic hepatitis C patients. <i>Scandinavian Journal of Gastroenterology</i> , 2019 , 54, 1033-1041	2.4	8
58	Altered diversity and composition of the gut microbiome in patients with cervical cancer. <i>AMB Express</i> , 2019 , 9, 40	4.1	29
57	The Commensal Microbiota and Viral Infection: A Comprehensive Review. <i>Frontiers in Immunology</i> , 2019 , 10, 1551	8.4	123
56	Colonizing multidrug-resistant bacteria and the longitudinal evolution of the intestinal microbiome after liver transplantation. <i>Nature Communications</i> , 2019 , 10, 4715	17.4	29
55	Gut-Liver Axis, Gut Microbiota, and Its Modulation in the Management of Liver Diseases: A Review of the Literature. <i>International Journal of Molecular Sciences</i> , 2019 , 20,	6.3	131
54	Short-term effects of direct-acting antiviral agents on inflammation and gut microbiota in hepatitis C-infected patients. <i>European Journal of Internal Medicine</i> , 2019 , 67, 47-58	3.9	14
53	Role of Gut Microbiota in Hepatocarcinogenesis. <i>Microorganisms</i> , 2019 , 7,	4.9	56
52	Characterization of gut microbiota in children with pulmonary tuberculosis. <i>BMC Pediatrics</i> , 2019 , 19, 445	2.6	19
51	Advances in Gut Microbiota of Viral Hepatitis Cirrhosis. <i>BioMed Research International</i> , 2019 , 2019, 9726786	3.86	14
50	The gut microbiota of hand, foot and mouth disease patients demonstrates down-regulated butyrate-producing bacteria and up-regulated inflammation-inducing bacteria. <i>Acta Paediatrica, International Journal of Paediatrics</i> , 2019 , 108, 1133-1139	3.1	7
49	Metabolomics and microbial composition increase insight into the impact of dietary differences in cirrhosis. <i>Liver International</i> , 2020 , 40, 416-427	7.9	7
48	Role of gut microbiota in liver disease. <i>American Journal of Physiology - Renal Physiology</i> , 2020 , 318, G84-G98	5.28	35
47	The Gut Microbiota: How Does It Influence the Development and Progression of Liver Diseases. <i>Biomedicines</i> , 2020 , 8,	4.8	12

46	Post-hoc analysis of a randomized controlled trial on the impact of pre-transplant use of probiotics on outcomes after liver transplantation. <i>Scientific Reports</i> , 2020 , 10, 19944	4.9	1
45	The Gut Barrier, Intestinal Microbiota, and Liver Disease: Molecular Mechanisms and Strategies to Manage. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	13
44	Neither black nor white: do altered intestinal microbiota reflect chronic liver disease severity?. <i>Gut</i> , 2021 , 70, 438-440	19.2	4
43	A story of liver and gut microbes: how does the intestinal flora affect liver disease? A review of the literature. <i>American Journal of Physiology - Renal Physiology</i> , 2020 , 318, G889-G906	5.1	43
42	Intestinal microbiota modulation in juvenile <i>Piaractus mesopotamicus</i> by supplementation with <i>Pyropia columbina</i> and β -carotene. <i>Aquaculture International</i> , 2020 , 28, 1001-1016	2.6	3
41	Microbiota changes and intestinal microbiota transplantation in liver diseases and cirrhosis. <i>Journal of Hepatology</i> , 2020 , 72, 1003-1027	13.4	65
40	Gut microbiota alterations are distinct for primary colorectal cancer and hepatocellular carcinoma. <i>Protein and Cell</i> , 2021 , 12, 374-393	7.2	14
39	Chronic Liver Diseases and the Microbiome-Translating Our Knowledge of Gut Microbiota to Management of Chronic Liver Disease. <i>Gastroenterology</i> , 2021 , 160, 556-572	13.3	17
38	Gut microbiome, liver immunology, and liver diseases. <i>Cellular and Molecular Immunology</i> , 2021 , 18, 4-17	15.4	45
37	Alterations of the Treatment-Naive Gut Microbiome in Newly Diagnosed Hepatitis C Virus Infection. <i>ACS Infectious Diseases</i> , 2021 , 7, 1059-1068	5.5	7
36	Research Progress of Intestinal Flora and Liver Related Diseases. <i>Advances in Clinical Medicine</i> , 2021 , 11, 3185-3190	0	
35	Improvement of Gut Diversity and Composition After Direct-Acting Antivirals in Hepatitis C Virus-Infected Patients With or Without Human Immunodeficiency Virus Coinfection. <i>Journal of Infectious Diseases</i> , 2021 , 224, 1410-1421	7	1
34	Gut microbiota signatures in <i>Schistosoma japonicum</i> infection-induced liver cirrhosis patients: a case-control study. <i>Infectious Diseases of Poverty</i> , 2021 , 10, 43	10.4	2
33	Dulaglutide Alone and in Combination with Empagliflozin Attenuate Inflammatory Pathways and Microbiome Dysbiosis in a Non-Diabetic Mouse Model of NASH. <i>Biomedicines</i> , 2021 , 9,	4.8	4
32	The Role of the Microbiome in Liver Cancer. <i>Cancers</i> , 2021 , 13,	6.6	4
31	Eradication of Chronic HCV Infection: Improvement of Dysbiosis Only in Patients Without Liver Cirrhosis. <i>Hepatology</i> , 2021 , 74, 72-82	11.2	6
30	The oral microbiome of treated and untreated chronic HCV infection: A preliminary study. <i>Oral Diseases</i> , 2021 ,	3.5	1
29	Gut Barrier and Microbiota in Cirrhosis.. <i>Journal of Clinical and Experimental Hepatology</i> , 2022 , 12, 625-638	1	1

28	Microbiota and viral hepatitis: State of the art of a complex matter. <i>World Journal of Gastroenterology</i> , 2021 , 27, 5488-5501	5.6	1
27	Synbiotics Supplements Lower the Risk of Hand, Foot, and Mouth Disease in Children, Potentially by Providing Resistance to Gut Microbiota Dysbiosis. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021 , 11, 729756	5.9	2
26	Pilot Sub-Study of the Effect of Hepatitis C Cure by Glecaprevir/Pibrentasvir on the Gut Microbiome of Patients with Chronic Hepatitis C Genotypes 1 to 6 in the Mythen Study. <i>Pharmaceuticals</i> , 2021 , 14,	5.2	1
25	Changes of Gut-Microbiota-Liver Axis in Hepatitis C Virus Infection. <i>Biology</i> , 2021 , 10,	4.9	3
24	A metagenomic study of the gut microbiome in PTBVS disease. <i>Microbes and Infection</i> , 2021 , 24, 104893	9.3	0
23	The impact of the gut microbiome on liver transplantation. <i>Current Opinion in Organ Transplantation</i> , 2021 , 26, 587-594	2.5	0
22	Multi-Omic Predictors of Steatohepatitis and Advanced Fibrosis in Children. <i>SSRN Electronic Journal</i> ,	1	
21	Hepatitis. 2020 , 1358-1367.e4		
20	Overview of the microbiota in the gut-liver axis in viral B and C hepatitis. <i>World Journal of Gastroenterology</i> , 2021 , 27, 7446-7461	5.6	1
19	Microbial Translocation in the Context of Hepatitis B Infection and Hepatitis D Infection.. <i>Open Forum Infectious Diseases</i> , 2021 , 8, ofaa496	1	0
18	Microbial Therapeutics in Liver Disease. 2021 ,		0
17	IgA anti-beta-2 glycoprotein I antibodies in chronic hepatitis C.. <i>Arab Journal of Gastroenterology</i> , 2022 ,	1.7	1
16	The biliary microbiome in ischemic-type biliary lesions can be shaped by stenting but is resilient to antibiotic treatment.. <i>Liver International</i> , 2022 ,	7.9	1
15	Compositions of gut microbiota before and shortly after hepatitis C viral eradication by direct antiviral agents.. <i>Scientific Reports</i> , 2022 , 12, 5481	4.9	0
14	Editorial: The Microbiome in Hepatobiliary and Intestinal Disease.. <i>Frontiers in Physiology</i> , 2022 , 13, 893074	7.6	0
13	Role of Microbiota in Viral Infections and Pathological Progression. <i>Viruses</i> , 2022 , 14, 950	6.2	1
12	From inflammation to fibrosis. 2022 , 25-53		
11	Trust Your Gut: The Association of Gut Microbiota and Liver Disease. <i>Microorganisms</i> , 2022 , 10, 1045	4.9	0

10	Stool microbiota show greater linkages with plasma metabolites compared to salivary microbiota in a multinational cirrhosis cohort. <i>Liver International</i> ,	7.9	○
9	Potential impact of gut <i>Lactobacillus acidophilus</i> and <i>Bifidobacterium bifidum</i> on hepatic histopathological changes in non-cirrhotic hepatitis C virus patients with different viral load. <i>Gut Pathogens</i> , 2022 , 14,	5.4	○
8	Structural and compositional segregation of the gut microbiota in HCV and liver cirrhotic patients: A clinical pilot study. 2022 , 171, 105739		○
7	Effects of direct anti-viral agents on the gut microbiota in patients with chronic hepatitis C. 2022 ,		○
6	Role of Intestinal Microbes in Chronic Liver Diseases. 2022 , 23, 12661		2
5	The Role of the Microbiota Gut-Liver Axis during HCV Chronic Infection: A Schematic Overview. 2022 , 11, 5936		○
4	Alterations of gut microbiome and effects of probiotic therapy in patients with liver cirrhosis: A systematic review and meta-analysis. 2022 , 101, e32335		○
3	The gut microbiota: A new perspective for tertiary prevention of hepatobiliary and gallbladder diseases. 10,		○
2	Intestinal flora plays a role in the progression of hepatitis-cirrhosis-liver cancer. 13,		○
1	Gut Microbiota Modulation: A Viable Strategy to Address Medical Needs in Hepatocellular Carcinoma and Liver Transplantation. 2023 ,		○